Then, perifosine, an inhibitor of the AKT pathway, was used to demonstrate whether ITGBL1 inhibits FBLN2 expression in GC cells and promotes anoikis resistance and metastasis through the AKT signalling pathway. This evidence concerns the gene FBLN2 and gastric cancer.